Penumbra (PEN) risk factors, FY2025 10-K

Risk Related to Our Proposed Merger

1. 01Uncertainty associated with our agreement to be acquired by Boston Scientific Corporation could have an adverse effect on our businessNew
2. 02The failure to complete the Merger could adversely affect our businessNew
3. 03We will continue to incur substantial transaction-related costs in connection with the MergerNew
4. 04We and our directors and officers may be subject to lawsuits relating to the MergerNew
5. 05Provisions of the Merger Agreement may deter alternative business combinations and could negatively impact our stock price if the Merger Agreement is terminated in certain circumstancesNew
6. 06Because the market price of Boston Scientific Corporation common stock may fluctuate, holders of our common stock cannot be certain of the market value of the consideration they will receive in the MergerNew

Business Risks

1. 07Our existing products may be rendered obsolete and we may be unable to effectively introduce and market new products or may fail to keep pace with advances in technology62% rewritten
2. 08changing clinical landscape, undertake more extensive marketing campaigns, have greater financial, marketing and other resources than us or be more successful in attracting potential customers and strategic partnersNew
3. 09We face significant competition, and if we are unable to compete effectively, we may not be able to achieve or maintain significant market penetration or improve our results of operations
4. 10We may not be able to achieve or maintain satisfactory pricing and margins for our products
5. 11We may not have the resources to successfully market and sell our products, which would adversely affect our business and results of operations
6. 12Third-party reimbursement may not be available or adequate for the procedures or sessions for which our products are used, and may be subject to change
7. 13We have generated a significant portion of our revenue and revenue growth from a limited number of product families, and our revenue and business prospects would be adversely affected if sales of any of these product families were to decline85% rewritten
8. 14Our dependence on key suppliers puts us at risk of interruptions in the availability of our products, which could reduce our revenue and adversely affect our results of operations
9. 15We cannot be certain that we will be able to manufacture our products in high volumes at commercially reasonable costs
10. 16We are required to maintain high levels of inventory, which consume a significant amount of our working capital and could lead to permanent write-downs or write-offs of our inventory
11. 17Defects or failures or alleged defects or failures associated with our products could lead to recalls, safety alerts, or product-related or securities litigation, as well as significant costs and negative publicity
12. 18Our products are continually the subject of clinical trials conducted by us, our competitors, or other third parties, the results of which may be unfavorable, or perceived as unfavorable, which could materially adversely affect our business, financial condition and results of operations
13. 19Negative publicity regarding our products or marketing tactics by competitors or other third parties could reduce demand for our products, which would adversely affect sales and our financial performance
14. 20Our corporate culture has contributed to our success, and if we cannot maintain this culture as we grow, we could lose the innovative approach, creativity, and teamwork fostered by our culture, and our business may be harmed
15. 21To successfully market and sell our products internationally, we must address a number of unique challenges applicable to international markets
16. 22We rely on our distributors to market and sell our products in certain international markets
17. 23Foreign currency exchange rates may adversely affect our results27% rewritten
18. 24We have experienced rapid growth in recent periods, and if we fail to manage our growth effectively, our business and results of operations may suffer
19. 25We depend on key personnel to operate our business and develop our products, and if we are unable to retain, attract and integrate qualified personnel, our ability to develop and successfully grow our business could be harmed
20. 26We depend on information technology systems to operate our business, and issues with maintaining, upgrading or implementing these systems, could have a material adverse effect on our business
21. 27Cost-containment efforts of our customers, purchasing groups and governmental organizations could have a material adverse effect on our sales and ability to achieve or maintain profitability55% rewritten
22. 28to purchase from our competitors due to the price or quality offered by such competitors, which could result in a decline in our sales and profitabilityNew

Regulatory Risks

1. 29We are subject to stringent domestic and foreign medical device regulations, which may impede the approval or clearance process for our products, hinder our development activities and manufacturing processes and, in some cases, result in the recall or seizure of previously approved or cleared products
2. 30If we modify our FDA cleared products, we may need to seek and obtain new clearances, which, if not granted, would prevent us from selling our modified products or require us to redesign our products
3. 31We may not receive necessary foreign regulatory approvals or clearances or otherwise comply with foreign regulations
4. 32We may not be able to meet regulatory quality requirements applicable to our manufacturing process
5. 33We are subject to federal, state and foreign healthcare laws and regulations that could result in significant liability, require us to change our business practices and restrict our operations in the future
6. 34If we are found to have improperly promoted our products for off-label uses, we may become subject to significant fines and other liability

Risks Related to Our Intellectual Property

1. 35We rely on a variety of intellectual property rights, and if we are unable to maintain or protect our intellectual property, our business and results of operations will be harmed
2. 36We may file lawsuits or initiate other proceedings to protect or enforce our patents or other intellectual property rights, which could be expensive, time consuming and unsuccessful
3. 37Our commercial success depends significantly on our ability to operate without infringing upon the intellectual property rights of third parties
4. 38Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future products
5. 39Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
6. 40If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
7. 41If we are unable to protect the confidentiality of our trade secrets and other proprietary information, our business and competitive position may be harmed

Risks Related to Our Finances and Capital Requirements

1. 42We may require additional financing in the future and may not be able to obtain such financing on favorable terms, if at all, which could force us to delay, reduce or eliminate our research and development activities or otherwise harm our business
2. 43By engaging in acquisitions and other business development arrangements, we will incur a variety of costs and may potentially face numerous risks that could adversely affect our business and operations
3. 44Fluctuations in our effective tax rate and changes to tax laws may adversely affect us

Risks Relating to Securities Markets and Investment in Our Common Stock

1. 45The price of our common stock may be volatile, and you could lose all or part of your investment
2. 46If our executive officers, directors and largest stockholders choose to act together, they may be able to significantly influence our management and operations, acting in their own best interests and not necessarily those of other stockholders
3. 47A sale of a substantial number of shares of our common stock in the public market could cause the market price of our common stock to drop significantly, even if our business is doing well
4. 48Techniques employed by short sellers have in the past and may in the future drive down the market price of our common stock
5. 49Our amended and restated certificate of incorporation, our third amended and restated bylaws and Delaware law contain provisions that could discourage another company from acquiring us and may prevent attempts by our stockholders to replace or remove our current management
6. 50We do not anticipate paying cash dividends, and accordingly, stockholders must rely on stock appreciation for any return on their investment
7. 51An additional valuation allowance against our deferred tax assets could require a charge to earnings, which could result in a negative impact on our results of operations
8. 52We cannot guarantee we will make any additional repurchases of our common stock under our share repurchase program or otherwise22% rewritten
9. 53It is difficult to forecast future performance, which may cause our financial results to fluctuate unpredictably
10. 54We are exposed to the risk of nonpayment by our customers, which could adversely affect our financial condition or results of operations
11. 55Natural disasters and other events beyond our control could harm our business
12. 56Failure to protect our information technology infrastructure against cyber-based attacks, network security breaches, service interruptions, or data corruption could significantly disrupt our operations and adversely affect our business and operating results
13. 57Our operations are subject to environmental, health and safety, and data privacy laws and regulations, compliance with which may be costly
14. 58We incur significant costs and devote substantial management time as a result of operating as a public company
15. 59If we fail to maintain an effective system of disclosure controls and procedures and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired67% rewritten
16. 60If securities or industry analysts publish inaccurate or unfavorable research about our business or cease publishing research, our stock price and trading volume could decline